PURE Bioscience (OTCMKTS:PURE) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

PURE Bioscience (OTCMKTS PURE) traded up 6.00% during mid-day trading on Friday, reaching $1.06. The company’s stock had a trading volume of 35,697 shares. The stock’s market cap is $66.47 million. The company has a 50 day moving average of $1.21 and a 200-day moving average of $1.06. PURE Bioscience has a 52-week low of $0.75 and a 52-week high of $1.36.

PURE Bioscience (OTCMKTS:PURE) last posted its earnings results on Thursday, June 8th. The company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). PURE Bioscience had a negative return on equity of 125.22% and a negative net margin of 276.96%. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $1 million. Equities analysts forecast that PURE Bioscience will post ($0.10) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “PURE Bioscience (PURE) Upgraded to Hold at ValuEngine” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/pure-bioscience-pure-upgraded-to-hold-at-valuengine/1536859.html.

PURE Bioscience Company Profile

PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with Analyst Ratings Network's FREE daily email newsletter.